The UK and US have signed a significant trade agreement that will preserve no import taxes on British drug shipments entering the American market.
Key Provisions of the Deal
In exchange for the tariff guarantee, the UK has pledged to boost spending on pharmaceuticals through the NHS. This move guarantees that import taxes on these key products will stay at zero for a timeframe of 36 months.
This deal follows earlier statements to significantly raise import taxes on branded pharmaceutical imports, with figures discussed reaching double the cost.
"This agreement between the United Kingdom strengthens the international landscape for new treatments and establishes long-overdue equity to American-British pharmaceutical trade," a release noted.
Commercial Importance
Medicines represent one of the the United Kingdom's most significant exports to the United States, which is clearly the primary destination for leading UK drugmakers.
Trade data reveal that in the year leading up to September, the UK exported medicines valued at £11.1bn to the US. This amount represented 17.4% of all goods exports in that timeframe.
"This guarantee protects employment, stimulates investment and facilitates the UK to become a global hub for biotech and pharma," a minister commented.
Detailed British Pledges
The deal entails several specific pledges from the British government:
- Price Threshold Increase: The UK will lift the affordability limit at which it deems new treatments to be too expensive by twenty-five percent.
- Increased NHS Spending: There is a goal to double total NHS spending on medicines from 0.3 percent of GDP to 0.6 percent over the next decade.
- Payback Limit: The sum manufacturers must refund to the NHS to prevent overspending will be limited at 15%. Last year, refunds exceeded twenty percent.
Broader Context
The deal follows a long-running row between the drug companies and the UK government over drug pricing and NHS adoption.
This friction were heightened by assertions that US customers were paying several times more for the equivalent treatments than patients in the UK and Europe.
Over the last 18 months, several major drug company projects in the UK have been halted or scrapped, while substantial expansions have been pledged toward US facilities.
One official publicly accepted that the NHS must spend more on drugs, noting that its expenditure on drugs had decreased as a share of its total funding over the previous ten-year period.
